Arizona Tribune - Redwood AI Launches Collaborative Research Project with UBC's Brent Page Lab Focused on Alzheimer's Drug Discovery

The project will focus on the design and optimization of inhibitors targeting NUDT5, a protein involved in biological stress-related signaling processes associated with neurodegeneration in Alzheimer's disease. Redwood will apply its computational platform to generate and evaluate virtual libraries of synthetically tractable analogue compounds, with the goal of helping to guide compound selection and accelerate the experimental work being carried out by the Page Lab. Through this process, Redwood aims to identify novel compound candidates with promising in-silico safety and efficacy profiles, including molecules that may not have been readily identified through traditional medicinal chemistry approaches. These computationally-designed candidates could then potentially be rapidly prioritized for synthesis and testing, thereby accelerating promising early discovery timelines.

By combining artificial intelligence with medicinal chemistry and biological testing, the project is intended to improve the efficiency of promising candidates for early-stage drug discovery and help advance them toward future preclinical development. The process of subsequent experimental validation by the Page Lab will be a key step in confirming whether computational predictions translate into real-world biological activity, addressing a critical challenge in drug discovery where many theoretically promising compounds fail to demonstrate efficacy in practice.

"We believe AI will play an increasingly central role in how new medicines are discovered and developed over the next decade. By pairing advanced computational design with world class academic science, we aim to help shorten the path from early discovery to stronger preclinical candidates. Programs like this one are building a foundation for a faster, more efficient approach to therapeutic innovation, and we see significant long term potential for this model across multiple disease areas," said Louis Dron, CEO of Redwood AI.

About Brent Page Lab at UBC

The Brent Page Lab is a leader in chemical probe design and medicinal chemistry, with a particular focus on structure-based drug discovery and experimental testing. Their work involves identifying how small molecules interact with protein targets using a wide range of techniques including molecular docking, chemical synthesis, and advanced biochemical assays. ⁴

About Redwood AI Corp.

Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The Company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI's platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.

ON BEHALF OF REDWOOD AI CORP.,

"Louis Dron"
Chief Executive Officer

For more information, please contact:

Louis Dron
Chief Executive Officer
Tel: +1 888 530 8488
Email: [email protected]

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution.

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements regarding the Company's collaboration with Brent Page Lab, its ability to carry out the research described here, and the potential for obtaining positive results that contribute to shortening the timeframe for drug discovery or further any of the Company's other clinical or business goals. Generally, forward-looking information can be identified by the use of forward- looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain acts, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved".

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information, including, without limitation, risks relating to the collaboration with Brent Page Lab; related to the failure of the Company's platform to contribute to drug discovery research as described herein; the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company's strategy or expectations regarding its software will materialize as anticipated or at all. Accordingly, readers should not place undue reliance on any such forward-looking information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

¹https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/

²https://www.statcan.gc.ca/o1/en/plus/5374-alzheimers-awareness-month

³https://www.alzint.org/about/dementia-facts-figures/dementia-statistics

⁴https://pharmsci.ubc.ca/directory/brent-page

SOURCE: Redwood AI Corp.

View the original press release on ACCESS Newswire

H.Romero--AT